myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Recruiting · Not applicable · NCT05204888
Conditions: COPD
At a glance
- Research payments reported, 2025
- $876,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 642
About the trial
- Sponsor
- Temple University (with Fisher and Paykel Healthcare)
- Tested
- myAirvo3 (device), Pulse oximeter (device)
- Dates
- Started 2022-02-02; completion 2027-03
- Results posted
- Not yet
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
From ClinicalTrials.gov, last updated 2025-02-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Fisher & Paykel Healthcare Limited reported $876,000 in research payments for this study in 2025 (3 payments).
Products named: Fisher & PAykel Healthcare
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.